Investing.com -- Tempus AI Inc (NASDAQ: TEM ) shares closed up 14.5% following the announcement of expanded strategic partnerships with AstraZeneca (NASDAQ: AZN ) and Pathos AI, Inc. The collaborations, disclosed on April 23, 2025, are set to develop the largest multimodal foundation model in oncology, aiming to enhance patient care and advance precision medicine.
The agreements, which include a substantial $200 million in data licensing and model development fees for Tempus, build on a previous partnership with AstraZeneca established in 2021. The new model will leverage Tempus’ extensive de-identified oncology data and AI-enabled platform to generate biological and clinical insights, discover new drug targets, and foster therapeutic development within the oncology field.
Tempus’ CEO, Eric Lefkofsky, expressed optimism about the impact of generative AI and large multimodal models on precision medicine in oncology, citing the company’s decade-long investment in data collection as a pivotal factor for the foundation model’s potential success. The collaboration is expected to support the individual efforts of all three parties to improve patient care.
AstraZeneca’s Chief AI and Data Scientist for Oncology R&D, Jorge Reis-Filho, highlighted the transformative effect of AI on cancer drug discovery and clinical development. He anticipates that the multimodal oncology foundation model will accelerate the clinical success rate across AstraZeneca’s diverse pipeline.
Pathos Board Member Mohamad Makhzoumi also commented on the significance of AI in drug discovery and development, expressing enthusiasm for the collaboration with Tempus and AstraZeneca and the expected improvements in patient outcomes.
While the news of these expanded agreements has driven Tempus AI’s stock upward, the true measure of success will be the practical outcomes of the partnership in advancing oncology treatments and patient care.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.